These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1093 related items for PubMed ID: 17850306

  • 1. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A, EDOS Group.
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, Vail GM, Beardsworth A.
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL, Ma M, Allmen Hv, Henderson SC, Harper K, Hornbuckle K.
    Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
    Ozgur BC, Gonenc F, Yazicioglu AH.
    Urol J; 2009 Jun; 6(4):267-71. PubMed ID: 20027555
    [Abstract] [Full Text] [Related]

  • 9. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    Lee J, Pommerville P, Brock G, Gagnon R, Mehta P, Krisdaphongs M, Chan M, Chan J, Dickson R.
    BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
    [Abstract] [Full Text] [Related]

  • 10. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D.
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST.
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [Abstract] [Full Text] [Related]

  • 12. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY, Lee SW, Kim SW, Yang DY, Park NC, Min KS, Park K, Paick JS, Dyachkova Y, Dwight T, Lee MS.
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U, Gleiter CH.
    Eur J Med Res; 2002 Oct 29; 7(10):435-46. PubMed ID: 12435622
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
    El-Meliegy A, Rabah D, Al-Mitwalli K, Mostafa T, Hussein T, Istarabadi M, Lei Y, Gurbuz S.
    Curr Med Res Opin; 2013 Jun 29; 29(6):707-17. PubMed ID: 23540436
    [Abstract] [Full Text] [Related]

  • 18. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P, Hedelin H, Ljunggren C.
    Eur Urol; 2006 May 29; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [Abstract] [Full Text] [Related]

  • 19. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
    Fusco F, Sicuteri R, Rossi A, Kontodimas S, Haro JM, Imbimbo C, Mirone V, Italian EDOS Study Group.
    Asian J Androl; 2009 Sep 29; 11(5):629-37. PubMed ID: 19701217
    [Abstract] [Full Text] [Related]

  • 20. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA, Satyanarayana R.
    Int J Impot Res; 2002 Dec 29; 14(6):466-71. PubMed ID: 12494279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.